Plus Therapeutics Regains Compliance with Nasdaq Listing Requirements

  • Investing.com
Plus Therapeutics Regains Compliance with Nasdaq Listing Requirements

Plus Therapeutics (NASDAQ: PSTV ), Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that it has received notification from The Nasdaq Stock Market LLC that the staff has determined that for the last 10 consecutive business days, from May 1, 2023 to May 12, 2023, the closing bid price of the Company’s common stock has been at $1.00 per share or greater. Therefore, the Company has regained compliance with Listing Rule 5550(a)(2). Accordingly, Nasdaq has advised that the matter is now closed.

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb

Error: File type not supported

Drop an image here or

100